STOCK TITAN

Lipocine (LPCN) DEF 14A Filings

LPCN NASDAQ

Here are the DEF 14A proxy statements from Lipocine Inc. (LPCN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LPCN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LPCN filings page.

Rhea-AI Summary

Lipocine Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 3, 2026 in Salt Lake City. Stockholders will elect four directors, ratify Tanner LLC as auditor for the year ending December 31, 2026, and cast an advisory “say‑on‑pay” vote on executive compensation.

The company also seeks approval to amend and restate its 2014 Stock and Incentive Plan, raising the annual individual award limit from 25,000 to 100,000 shares and increasing the total shares authorized for issuance under the plan from 600,000 to 1,000,000. As of the April 6, 2026 record date, 8,025,115 common shares were outstanding, and the Board unanimously recommends voting in favor of all proposals.